The parties will focus on developing products for hatcheries, the facilities where eggs are hatched before the chickens move to grow-out farms. As part of the agreement, Boehringer Ingelheim will market and distribute Novozymes’ FloraMax probiotic product for the U.S. poultry industry. Boehringer Ingelheim plans on expanding to other markets globally in the coming years.
“Boehringer Ingelheim is continuously exploring new science, products and industry categories, to deliver a powerful range of innovative solutions with a focus on customer needs. Poultry producers are looking for improved ways to deliver on the growing global need for sustainable protein,” said George Heidgerken, global head of livestock at Boehringer Ingelheim.
Probiotics are naturally occurring, live microbes that can improve the gut flora of poultry and other animals. Robust gut flora can significantly improve animal health, thereby providing a natural alternative to antibiotic growth promoters. Rising global consumption of meat, and legislative and consumer-driven curbs on the use of antibiotics as growth promoters in animal farming have increased demand for alternatives such as probiotics.
“We are excited to collaborate with Boehringer Ingelheim to develop a range of probiotic solutions for poultry that will improve sustainability in the industry,” said Susanne Palsten Buchardt, vice president, animal health & nutrition at Novozymes. “The collaboration is an important step in solidifying Novozymes’ capabilities within probiotics and helping poultry producers deliver greater quantities of safe, affordable protein. Utilizing Boehringer Ingelheim’s close relationships with large-scale producers, Novozymes will gain valuable access to new distribution channels and customers, many of which are seeking sustainable alternatives to antibiotic growth promoters.”